Emerging biological therapies for the treatment of malignant pleural mesothelioma

References

• Shavelle R, Vavra-Musser K, Lee J, et al. Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int. 2017;2017:1–8.
   Google Scholar
• Jane Henley S, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008. Int J Occup Environ Health. 2013;19(1):1–10.
   PubMed Web of Science ®Google Scholar
• Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study. Ann Thorac Surg. 2018;105(2):432–437.
   PubMed Web of Science ®Google Scholar
• Meyerhoff RR, Yang C-FJ, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23–32.
   PubMed Web of Science ®Google Scholar
• Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28(8):1043–1057.
   PubMed Web of Science ®Google Scholar
• Odgerel C-O, Takahashi K, Sorahan T, et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851–858.
   PubMed Web of Science ®Google Scholar
• Bueno R, Opitz I. Surgery in malignant pleural mesothelioma. J Thorac Oncol. 2018;13(11):1638–1654.
   PubMed Web of Science ®Google Scholar
• Baas P, Fennell D, Kerr KM, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v31–v39.
   PubMed Web of Science ®Google Scholar
• Bibby AC, Halford P, De Fonseka D, et al. The prevalence and clinical relevance of nonexpandable lung in malignant pleural mesothelioma. a prospective, single-center cohort study of 229 patients. Ann Am Thorac Soc. 2019;16(10):1273–1279.
   PubMed Web of Science ®Google Scholar
• Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591–1603.
   PubMed Web of Science ®Google Scholar
• Spirtas R, Heineman EF, Bernstein L, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med. 1994;51(12):804–811.
   PubMed Web of Science ®Google Scholar
• Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer. 1982;45(1):124–135.
   PubMed Web of Science ®Google Scholar
• Reid A, De Klerk NH, Magnani C, et al. Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax. 2014;69(9):843–850.
   PubMed Web of Science ®Google Scholar
• Bahk J, Choi Y, Lim S, et al. Why some, but not all, countries have banned asbestos. Int J Occup Environ Health. 2013;19(2):127–135.
   PubMed Web of Science ®Google Scholar
• Marsili D, Comba P. Asbestos case and its current implications for global health. Ann Ist Super Sanita. 2013;49(3):249–251.
   PubMed Web of Science ®Google Scholar
• Oddone E, Bollon J, Nava CR, et al. Predictions of mortality from pleural mesothelioma in Italy after the ban of asbestos use. IJERPH. 2020;17(2):607.
   Google Scholar
• Kwak KM, Paek D, Hwang S, et al. Estimated future incidence of malignant mesothelioma in South Korea: projection from 2014 to 2033. Pershouse MA, editor. PLoS ONE. 2017;12(8):e0183404.
   PubMed Web of Science ®Google Scholar
• Guo Z, Carbone M, Zhang X, et al. Improving the accuracy of mesothelioma diagnosis in China. J Thorac Oncol. 2017;12(4):714–723.
   PubMed Web of Science ®Google Scholar
• Jadhav A, Gawde N. Current asbestos exposure and future need for palliative care in India. Indian J Palliat Care. 2019;25(4):587.
   PubMed Web of Science ®Google Scholar
• Opitz I, Weder W. Pleural mesothelioma: is the surgeon still there? Ann Oncol. 2018;29(8):1710–1717.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Rimner A, Simone CB, et al. The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and mesothelioma applied research foundation. J Thorac Oncol. 2019;14(7):1172–1183.
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50(3):373–381.
   PubMed Web of Science ®Google Scholar
• Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20(8):2902–2906.
   PubMed Web of Science ®Google Scholar
• Servais EL, Colovos C, Rodriguez L, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18(9):2478–2489.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16(3):192–197.
   PubMed Web of Science ®Google Scholar
• Marshall K, Jackson S, Jones J, et al. Homozygous deletion of CDKN2A in malignant mesothelioma: diagnostic utility, patient characteristics and survival in a UK mesothelioma centre. Lung Cancer. 2020;150:195–200.
   PubMed Web of Science ®Google Scholar
• Yang H, Xu D, Schmid RA, et al. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Ther Adv Med Oncol. 2020;12:1758835920971421.
   Web of Science ®Google Scholar
• Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(4):565–576.
   PubMed Web of Science ®Google Scholar
• Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76–81.
   PubMed Web of Science ®Google Scholar
• Hassan R, Morrow B, Thomas A, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA. 2019;116(18):9008–9013.
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
   PubMed Web of Science ®Google Scholar
• Cedrés S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). Gangopadhyay N, editor. PLoS ONE. 2015;10(3):e0121071.
   PubMed Web of Science ®Google Scholar
• Kao SC, Cheng YY, Williams M, et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol. 2017;12(9):1421–1433.
   PubMed Web of Science ®Google Scholar
• Michielin O, Atkins MB, Koon HB, et al. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8(2):e000948.
   PubMed Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649.
   PubMed Web of Science ®Google Scholar
• Chee SJ, Lopez M, Mellows T, et al. Evaluating the effect of immune cells on the outcome of patients with mesothelioma. Br J Cancer. 2017;117(9):1341–1348.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. JCO. 2003;21(14):2636–2644.
   PubMed Web of Science ®Google Scholar
• Sun HH, Vaynblat A, Pass HI. Diagnosis and prognosis—review of biomarkers for mesothelioma. Ann Transl Med. 2017;5(11): 244–244.
   Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. JCO. 2019;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. JCO. 2006;24(9):1443–1448.
   PubMed Web of Science ®Google Scholar
• Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol. 2008;3(7):756–763.
   PubMed Web of Science ®Google Scholar
• Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the european organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. JCO. 2005;23:6881–6889.
   PubMed Web of Science ®Google Scholar
• Nicoletti SLV, Cherubini C, Papi M, et al. Cisplatin-raltitrexed vs cisplatin-pemetrexed in the treatment of advanced pleural mesothelioma. final results of a network meta-analysis. Ann Oncol. 2016;27:iv7.
   Google Scholar
• Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. JCO. 2008;26(10):1698–1704.
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Kass SL, Woo K, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014;84(3):271–274.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009;63(1):94–97.
   PubMed Web of Science ®Google Scholar
• Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer. 2003;104(5):603–610.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–1414.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ismaila N, Armato SG, et al. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline. JCO. 2018;36(13):1343–1373.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: malignant pleural mesothelioma, version 3.2016. J Natl Compr Canc Netw. 2016;14(7):825–836.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782.
   PubMed Web of Science ®Google Scholar
• Grosso F, Steele N, Novello S, et al. Nintedanib plus pemetrexed/cisplatin in patients with MPM: phase II findings from the placebo-controlled LUME-Meso trial. Ann Oncol. 2017;28:ix74.
   Web of Science ®Google Scholar
• Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569–580.
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95–106.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623–630.
   PubMed Web of Science ®Google Scholar
• Desai A, Karrison T, Rose B, et al. OA08.03 phase II trial of pembrolizumab (NCT02399371) In previously-treated malignant mesothelioma (MM): final analysis. J Thorac Oncol. 2018;13(10):S339.
   Web of Science ®Google Scholar
• Yap TA, Nakagawa K, Fujimoto N, et al. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med. 2021;S2213260020305154. Doi:10.1016/S2213-2600(20)30515-4
   Google Scholar
• Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485–5492.
   PubMed Web of Science ®Google Scholar
• Hayashi H, Okada M, Kijima T, et al. 1895MO Three-year follow-up results of the MERIT trial: a Japanese phase II study of nivolumab in malignant pleural mesothelioma. Ann Oncol. 2020;31:S1076.
   Web of Science ®Google Scholar
• Popat S, Curioni-Fontecedro A, Dafni U, et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734–1745.
   PubMed Web of Science ®Google Scholar
• Fennell DA, Kirkpatrick E, Cozens K, et al. CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. Trials. 2018;19(1):233.
   PubMedGoogle Scholar
• Fennell D, Ottensmeier C, Califano R, et al. PS01.11 nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 trial. J Thorac Oncol. 2021;16(3):S62.
   Web of Science ®Google Scholar
• Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–253.
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451–460.
   PubMed Web of Science ®Google Scholar
• Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260–270.
   PubMed Web of Science ®Google Scholar
• Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386.
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Pasello G. Immune checkpoint inhibitors in mesothelioma: a turning point. Lancet. 2021;397(10272):348–349.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Lesterhuis WJ, Kok P-S, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020;21(9):1213–1223.
   PubMed Web of Science ®Google Scholar
• Forde PM, Sun Z, Anagnostou V, et al. PrE0505: phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. JCO. 2020;38(15_suppl): 9003–9003. DOI:10.1200/JCO.2020.38.15_suppl.9003.
   Google Scholar
• Lv J, Li P. Mesothelin as a biomarker for targeted therapy. Biomark Res. 2019;7(1):18.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Antonia S, Bautista Y, et al. LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): patient-reported outcomes (PROs) from checkmate 743. Ann Oncol. 2020;31:S1441.
   Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Betti M, Casalone E, Ferrante D, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;405:38–45.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505.
   PubMed Web of Science ®Google Scholar
• De Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102.
   PubMed Web of Science ®Google Scholar
• Passiglia F, Bironzo P, Righi L, et al. A prospective phase II single-arm study of niraparib plus dostarlimab in patients with advanced non–small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes: rationale and study design. Clin Lung Cancer. 2021;22(1):e63–e66.
   PubMed Web of Science ®Google Scholar
• Fennell D, Hudka M, Darlison L, et al. P2.06-02 Mesothelioma Stratified Therapy (MiST): a phase IIA umbrella trial for accelerating the development of precision medicines. J Thorac Oncol. 2019;14(10):S755–S756.
   Web of Science ®Google Scholar
• Friedman RC, Farh KK-H, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008;19(1):92–105.
   PubMed Web of Science ®Google Scholar
• Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–3135.
   PubMed Web of Science ®Google Scholar
• Van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386–1396.
   PubMed Web of Science ®Google Scholar
• Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2016;5(1):18046.
   Web of Science ®Google Scholar
• Giladi M, Munster M, Blat R, et al. Abstract 5361: in vitro results and electric fields simulations suggest Tumor Treating Fields (TTFields) to be an effective treatment against Mesothelioma. Experimental and Molecular Therapeutics [Internet]. Am Assoc Cancer Res. 2015; 5361–5361. [cited 2021 Feb 16]. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2015-5361
   Google Scholar
• Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol. 2019;20(12):1702–1709.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Alley E, Stevenson JP, et al. Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNα combined with chemotherapy. Clin Cancer Res. 2016;22(15):3791–3800.
   PubMed Web of Science ®Google Scholar
• Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.
   PubMedGoogle Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20(23):5927–5936.
   PubMed Web of Science ®Google Scholar
• Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen: SS1P Plus Chemotherapy for Mesothelioma. Cancer. 2014;120(21):3311–3319.
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13(17):5144–5149.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Novello S, Fennell D, et al. OA 02.01 randomized phase ii study of anetumab ravtansine or vinorelbine in patients with metastatic pleural mesothelioma. J Thorac Oncol. 2017;12(11):S1746.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med. 2010;181(12):1383–1390.
   PubMed Web of Science ®Google Scholar
• Aerts JGJV, De Goeje PL, Cornelissen R, et al. Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res. 2018;24(4):766–776.
   PubMed Web of Science ®Google Scholar
• on behalf of the DENIM team*, Belderbos RA, Baas P, Berardi R, et al. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: dENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res. 2019;8(3):280–285.
   PubMed Web of Science ®Google Scholar
• Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133–146.
   PubMed Web of Science ®Google Scholar
• Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26–37.
   PubMed Web of Science ®Google Scholar
• Adusumilli PS, Zauderer MG, Rusch VW, et al. Abstract CT036: a phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy. Clinical trials [internet]. Am Assoc Cancer Res. 2019;CT036–CT036. [cited 2021 Feb 19]. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2019-CT036
   Google Scholar
• Curioni A, Britschgi C, Hiltbrunner S, et al. A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells. Ann Oncol. 2019;30:v501.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
   PubMed Web of Science ®Google Scholar